BR112021012027A2 - Molécula bifuncional direcionada contra pd-1 humano - Google Patents

Molécula bifuncional direcionada contra pd-1 humano

Info

Publication number
BR112021012027A2
BR112021012027A2 BR112021012027A BR112021012027A BR112021012027A2 BR 112021012027 A2 BR112021012027 A2 BR 112021012027A2 BR 112021012027 A BR112021012027 A BR 112021012027A BR 112021012027 A BR112021012027 A BR 112021012027A BR 112021012027 A2 BR112021012027 A2 BR 112021012027A2
Authority
BR
Brazil
Prior art keywords
bifunctional molecule
against human
targeted against
molecule targeted
bifunctional
Prior art date
Application number
BR112021012027A
Other languages
English (en)
Inventor
Aurore Morello
Caroline Mary
Nicolas Poirier
Virginie Thepenier
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of BR112021012027A2 publication Critical patent/BR112021012027A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

molécula bifuncional direcionada contra pd-1 humano. a presente invenção fornece a molécula bifuncional que compreende um anticorpo anti-hpd-1 humanizado ou fragmento de ligação a antígeno do mesmo ligado a um agente imunoterapêutico capaz de melhorar especificamente a resposta imunológica e usos do mesmo.
BR112021012027A 2018-12-21 2019-12-17 Molécula bifuncional direcionada contra pd-1 humano BR112021012027A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306799 2018-12-21
PCT/EP2019/085781 WO2020127369A1 (en) 2018-12-21 2019-12-17 Bifunctional molecule directed against human pd-1

Publications (1)

Publication Number Publication Date
BR112021012027A2 true BR112021012027A2 (pt) 2021-11-03

Family

ID=65628502

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021012027A BR112021012027A2 (pt) 2018-12-21 2019-12-17 Molécula bifuncional direcionada contra pd-1 humano

Country Status (10)

Country Link
US (1) US20220025050A1 (pt)
EP (1) EP3897845A1 (pt)
JP (1) JP2022515223A (pt)
KR (1) KR20210107058A (pt)
CN (1) CN113573782A (pt)
AU (1) AU2019406453A1 (pt)
BR (1) BR112021012027A2 (pt)
CA (1) CA3122899A1 (pt)
IL (1) IL284052A (pt)
WO (1) WO2020127369A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3573600T1 (sl) 2017-01-25 2022-07-29 Ose Immunotherapeutics Postopek za proizvodnjo obstojne emulzije za dostavo peptida
CN111164100B (zh) 2017-08-03 2024-03-12 美国安进公司 白介素-21突变蛋白和治疗方法
CR20210319A (es) 2018-01-12 2021-07-27 Amgen Inc ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330)
KR102371173B1 (ko) 2018-12-21 2022-03-04 오제 이뮈노테라프틱스 인간화된 항-인간-pd-1 항체
EP3898677A1 (en) * 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
JP2023521238A (ja) * 2020-04-15 2023-05-23 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫複合体
CN116323657B (zh) * 2020-09-24 2023-12-08 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
WO2022214652A1 (en) * 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
CN117460746A (zh) * 2021-06-17 2024-01-26 和铂医药(上海)有限责任公司 靶向pd1和/或ox40的特异性结合蛋白
IL310217A (en) * 2021-07-23 2024-03-01 Akeso Biopharma Inc Pharmacy preparation and use
WO2023046047A1 (zh) * 2021-09-27 2023-03-30 盛禾(中国)生物制药有限公司 一种异源二聚体蛋白质及其应用
WO2023221936A1 (zh) * 2022-05-17 2023-11-23 苏州创胜医药集团有限公司 双功能蛋白质及其制剂和用途
CN116987198B (zh) * 2023-09-28 2023-12-26 军科正源（北京）药物研究有限责任公司 一种靶向人pd-l1的融合蛋白及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
US5275285A (en) 1992-12-30 1994-01-04 Clegg Industries Business card holder with sound generating microchip
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
IL136544A0 (en) 1997-12-05 2001-06-14 Scripps Research Inst Humanization of murine antibody
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US7371371B2 (en) 2001-08-13 2008-05-13 University Of Southern California Interleukin-2 mutants with reduced toxicity
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
PT2066796E (pt) 2006-09-20 2011-10-11 Mt Biomethan Gmbh Procedimento e dispositivo para a separação do metano e do dióxido de carbono do biogás
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
SI2673294T1 (sl) 2011-02-10 2016-08-31 Roche Glycart Ag Mutirani polipeptidi interlevkina-2
ES2843546T3 (es) 2014-04-18 2021-07-19 The Research Foundation Of The State Univ Of New York Anticuerpos humanizados anti-antígeno-TF
CA2982984C (en) * 2015-04-20 2023-10-17 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
AU2016306597A1 (en) * 2015-08-07 2018-02-22 Pieris Pharmaceuticals Gmbh Novel fusion polypeptide specific for LAG-3 and PD-1
CN105111314B (zh) * 2015-08-13 2019-01-08 成都百世博生物技术有限公司 一种新型融合蛋白、药物组合物及其制备方法和用途
RU2022102624A (ru) * 2015-10-01 2022-03-10 Хит Байолоджикс, Инк. Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
BR112018014615A2 (pt) 2016-01-20 2018-12-11 The Scripps Research Institute composições de anticorpo para ror1 e métodos relacionados
CN117024599A (zh) * 2016-02-05 2023-11-10 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
CA3035932A1 (en) 2016-09-14 2018-03-22 Abbvie Biotherapeutics Inc. Anti-pd-1 antibodies and their uses
CN108250303B (zh) * 2016-12-19 2023-01-03 南京金斯瑞生物科技有限公司 单域抗体融合蛋白及其应用
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
PT3606946T (pt) 2017-04-03 2022-10-17 Hoffmann La Roche Imunoconjugados de um anticorpo anti-pd-1 com uma il-2 mutante ou com il-15
EP3609922A2 (en) 2017-04-13 2020-02-19 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
CA3076611A1 (en) 2017-09-23 2019-03-28 Memorial Sloan Kettering Cancer Center A33 antibody compositions and methods of using the same in radioimmunotherapy
AU2019232523A1 (en) 2018-03-05 2020-09-03 Etablissement Francais Du Sang Recombinant single chain immunoglobulins

Also Published As

Publication number Publication date
IL284052A (en) 2021-08-31
AU2019406453A1 (en) 2021-07-22
CA3122899A1 (en) 2020-06-25
EP3897845A1 (en) 2021-10-27
US20220025050A1 (en) 2022-01-27
JP2022515223A (ja) 2022-02-17
CN113573782A (zh) 2021-10-29
WO2020127369A1 (en) 2020-06-25
KR20210107058A (ko) 2021-08-31

Similar Documents

Publication Publication Date Title
BR112021012027A2 (pt) Molécula bifuncional direcionada contra pd-1 humano
CY1124723T1 (el) Μορια προσδεσης pd-1 και μεθοδοι χρησης αυτων
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
ECSP20076683A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
PH12019502463A1 (en) Anti-cd33 antibodies and methods of use thereof
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
BR112016022841A8 (pt) Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo
BR112021007902A2 (pt) Anticorpo anti-cd73, fragmento de ligação ao antigênio e aplicação dos mesmos
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
BR112019004995A2 (pt) anticorpo que se liga especificamente a pd-1 e fragmento funcional do mesmo
MX2019011520A (es) Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos.
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
CL2022000030A1 (es) Moléculas de unión a claudina-6 y usos de las mismas
AR114129A1 (es) ANTICUERPOS TERAPÉUTICOS DIRIGIDOS CONTRA sPLA2-GIB Y SUS USOS
BR112022006620A2 (pt) Anticorpos contra o receptor de poliovírus (pvr) e seus usos
BR112019007147A2 (pt) anticorpos anti-o1 e usos dos mesmos
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
CL2021000736A1 (es) Receptor de antígeno quimérico.
BR112023025433A2 (pt) Anticorpos anti-ccr8 e seus usos
MX2018004406A (es) Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae.
BR112022003635A2 (pt) Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso